New management options for osteoporosis with emphasis on SERMs

References

• Albright F, Bloomberg E, Smith PH. Postmenopausal osteoporosis. Trans Assoc Am Physicians 1940;55:298–305
   Google Scholar
• Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis: its clinical features. J Am Med Assoc 1941;116:2465–74
   Google Scholar
• Reifenstein EC Jr, Albright F. The metabolic effects of steroid hormones in osteoporosis. J Clin Invest 1947;26:24–56
   PubMed Web of Science ®Google Scholar
• Albright F. Osteoporosis. Ann Intern Med 1947;27:861–82
   PubMed Web of Science ®Google Scholar
• O'Malley BW. Mechanisms of action of steroid hormones. N Engl J Med 1971;284:370–7
   PubMed Web of Science ®Google Scholar
• McKenna NJ, O'Malley BW: Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002;108:465–74
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2–12
   PubMed Web of Science ®Google Scholar
• Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 2013;8:135–55
   PubMedGoogle Scholar
• Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852–6
   PubMed Web of Science ®Google Scholar
• Jordan VC. Designer estrogens. Sci Am 1998;279:60–7
   PubMed Web of Science ®Google Scholar
• Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006;24:675–80
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7
   PubMed Web of Science ®Google Scholar
• Eng-Wong J, Reynolds JC, Venzon D, et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006;91:3941–6
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Eastell R, et al.; Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514–24
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Stock JL, Barrett-Connor E, et al. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res 2008;23:112–20
   PubMed Web of Science ®Google Scholar
• Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558–65
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189–97
   PubMed Web of Science ®Google Scholar
• Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat 2001;65:125–34
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751–61
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847–57
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125–37
   PubMed Web of Science ®Google Scholar
• Grady D, Cauley JA, Stock JL, et al. Effect of raloxifene on all-cause mortality. Am J Med 2010;123:469.e1–7
   Google Scholar
• Sato M, Turner CH, Wang T, et al. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 1998;287:1–7
   PubMed Web of Science ®Google Scholar
• Bolognese M, Krege JH, Utian WH, et al. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. J Clin Endocrinol Metab 2009;94:2284–9
   PubMed Web of Science ®Google Scholar
• Cummings SR, McClung M, Reginster JY, et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 2011;26:397–404
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bhattoa HP, Neven P, et al. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass. Menopause 2012;19:41–7
   PubMed Web of Science ®Google Scholar
• Downs RW Jr, Moffett AM, Ghosh A, et al. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass. Osteoporos Int 2010;21:1215–26
   PubMed Web of Science ®Google Scholar
• Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998;139:2068–76
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686–96
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 2010;102:1706–15
   PubMed Web of Science ®Google Scholar
• Ensrud K, LaCroix A, Thompson JR, et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation 2010;122:1716–24
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Neven P, Cummings S, et al. Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause 2011;18:17–22
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999–4008
   PubMed Web of Science ®Google Scholar
• Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525–35
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923–34
   PubMed Web of Science ®Google Scholar
• Silverman SL, Chines AA, Kendler DL, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012;23:351–63
   PubMed Web of Science ®Google Scholar
• Palacios S, Silverman SL, de Villiers TJ, et al. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause 2015;22:806–13
   PubMed Web of Science ®Google Scholar
• Christiansen C, Chesnut CH III, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010;11:130
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011;22:567–76
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045–52
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014;99:E189–98
   PubMed Web of Science ®Google Scholar
• McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126:13–20
   PubMed Web of Science ®Google Scholar
• Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007;9(Suppl 1):S7
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 2013;24:227–35
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–65
   PubMed Web of Science ®Google Scholar
• Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 2013;98:4483–92
   PubMed Web of Science ®Google Scholar
• Okada N, Kawazoe K, Teraoka K, et al. Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull 2013;36:1622–6
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688–703
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41
   PubMed Web of Science ®Google Scholar
• Rodan SB, Duong LT. Cathepsin K – a new molecular target for osteoporosis. IBMS BoneKey 2008;5:16–24
   Google Scholar
• Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: 5 years of continued therapy in a phase 2 study. J Bone Miner Res 2012;27:2251–8
   PubMed Web of Science ®Google Scholar
• McClung MR, Langdahl B, Papapoulos S, et al. Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the Phase III Long-term Odanacatib Fracture Trial (LOFT). Presented at the European Calcified Tissue Society, Rotterdam, March 2015; IBMS BoneKey 2015;13:9, Abstr OC4.4
   Google Scholar
• van Lierop AH, Hamdy NAT, van Bezooijen RL, et al. The role of sclerostin in the pathophysiology of sclerosing bone dysplasias. Clin Rev Bone Min Metab 2012;10:108–16
   Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Effects of romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:467–74
   PubMed Web of Science ®Google Scholar
• Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 2015;30:216–24
   PubMed Web of Science ®Google Scholar